The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The regenerative medicine market is projected to reach $578 billion by 2033 but faces a significant manufacturing hurdle: scaling production of living therapeutics. While companies like Prime Medicine, Madrigal Pharmaceuticals, Iovance Biotherapeutics, and Denali Therapeutics are making progress, Avaí Bio, in a joint venture with Austrianova, has solved a critical foundational step by initiating the manufacturing of a Master Cell Bank for its α-Klotho protein therapy. This approach, combined with Austrianova's Cell-in-a-Box® encapsulation technology, aims to transform patient-specific treatments into scalable, off-the-shelf products.
Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Rating of "Moderate Buy" from Brokerages
Prime Medicine, Inc. (NASDAQ:PRME) has received a "Moderate Buy" consensus rating from brokerages, with an average 1-year price target of $7.38 from nine analysts. Recent analyst activities include Oppenheimer initiating coverage with an "outperform" rating and a $11 target, and Lifesci Capital upgrading the stock to "strong-buy." The article also notes that institutions own approximately 70.37% of the stock, with significant inflows during the fourth quarter.
2026: The Pivotal Year for Prime Medicine's Clinical Ambitions
Prime Medicine is approaching a critical period in 2026, shifting its focus from initial clinical proof-of-concept to broader in-body application of its gene-editing technology. The company, financially stable into 2027 with Bristol Myers Squibb's support, plans to advance both ex vivo (PM359 for chronic granulomatous disease) and in vivo therapies. Key milestones for 2026 include regulatory filings for Wilson disease and Alpha-1 antitrypsin deficiency, which will validate its prime-editing platform against CRISPR-based competitors.
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3% - What's Next?
Prime Medicine (NASDAQ:PRME) saw its stock price drop by 7.3% on Friday, trading at an intraday low of $3.36 with significantly reduced trading volume. Despite this decline, analysts maintain a "Moderate Buy" consensus rating with an average target price of $7.38. Institutional investors, including Alphabet, ARK, State Street, Vanguard, and Farallon, have recently increased their stakes in the company, which has a market capitalization of approximately $607.6 million.
PRME Stock Price, Quote & Chart | PRIME MEDICINE INC (NASDAQ:PRME)
This article provides an overview of PRIME MEDICINE INC (NASDAQ:PRME) stock, highlighting its current price, performance metrics, and key statistics. It also includes technical and fundamental analysis ratings from ChartMill, recent earnings data, analyst forecasts, and company information. The article indicates that PRME is a biotechnology company focused on developing genetic therapies.
Prime Medicine, Inc. (PRME) reports Q4 loss, misses revenue estimates
The article reports that Prime Medicine, Inc. (PRME) announced a Q4 loss and missed revenue estimates. This financial performance is likely to be a key point of discussion for investors and analysts following the company.
Prime Medicine slips after Q4 updates
The article reports that Prime Medicine's stock slipped following its Q4 updates. Further details regarding the Q4 updates and reasons for the slip are unavailable as the content is currently "MSN".
Casdin Capital LLC Acquires 1,600,000 Shares of Prime Medicine, Inc. $PRME
Casdin Capital LLC significantly increased its stake in Prime Medicine, Inc. (NASDAQ:PRME) by 102.1% in Q3, purchasing an additional 1,600,000 shares to hold a total of 3,167,175 shares valued at $17.55 million. This investment makes Prime Medicine the 14th largest holding in Casdin's portfolio, representing 1.5% of its total assets. Despite a "Moderate Buy" consensus rating from analysts with a target price of $7.75, the stock currently trades around $3.65, showcasing varied analyst opinions and significant institutional ownership.
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer
Oppenheimer initiated coverage on Prime Medicine (NYSE:PRME) with an "Outperform" rating and an $11 price target, indicating a potential 187.21% upside. Lifesci Capital also started coverage with an "Outperform" rating and a $6 price target. The company currently holds a "Moderate Buy" consensus rating and a $7.75 consensus price target from analysts, with 70.37% of its stock owned by institutional investors.
Oppenheimer bullish on Prime Medicine, initiates with an Outperform
Oppenheimer has initiated coverage of Prime Medicine (PRME) with an Outperform rating and an $11 price target, citing the company's leading gene-editing approach and a strong pipeline including a potentially best-in-class AATD program. The firm believes Prime Medicine's prime editing technology, validated by early clinical data and a partnership with BMS, offers significant upside potential, estimating 100%-200% growth within 10-15 months based on peer valuations. Oppenheimer also suggests that the stock's high short interest is not reflective of its fundamental value.
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) announced its first-quarter 2024 financial results, reporting a loss of $0.62 per share. This figure represents a narrower loss than the Zacks Consensus Estimate of a $0.78 loss but is 26.53% wider than the loss reported in the prior-year quarter. The company also missed revenue estimates, reporting $0.85 million against an anticipated $1.5 million.
Prime Medicine (NASDAQ:PRME) Trading Down 6.3% - Here's What Happened
Prime Medicine (NASDAQ:PRME) saw its stock price drop by 6.3% during Wednesday's mid-day trading to $3.79, with trading volume significantly lower than its daily average. Analyst ratings are split, with Lifesci Capital upgrading it to a "strong-buy" while Weiss Ratings reiterated a "sell," resulting in a "Moderate Buy" consensus from MarketBeat. The biotechnology company, focused on Prime Editing technology, has a market cap of $681.6 million and a negative P/E ratio.
[EFFECT] Prime Medicine, Inc. SEC Filing
This article reports on an EFFECT SEC filing by Prime Medicine, Inc. (PRME), indicating a neutral impact and sentiment. The filing, with an effectiveness date of March 4, 2026, involves a Notice of Effectiveness for an Accession Number 0001894562-26-000009. The article provides details like the company's CIK, file number, and a link to the original filing.
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway
Prime Medicine (PRME) is focusing its efforts on its in vivo liver franchise, with a cash runway of $191.4 million extending into 2027. The company is advancing lead liver-focused programs in Wilson Disease and Alpha-1 Antitrypsin Deficiency, expecting initial clinical data in 2027, and is also pursuing accelerated FDA approval for its Chronic Granulomatous Disease/CGD program. Despite a net loss in 2025, Prime Medicine maintained stable R&D expenses by optimizing its workforce and prioritizing clinical milestones.
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway
Prime Medicine (PRME) is shifting its focus to its in vivo liver franchise, supported by a $191.4 million cash runway into 2027. Despite a net loss, the company is advancing lead programs for Wilson Disease and Alpha-1 Antitrypsin Deficiency, expecting initial clinical data in 2027. Prime Medicine is also pursuing accelerated FDA approval for its CGD candidate, PM359, following positive Phase 1/2 data.
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC
ARK Investment Management LLC significantly increased its stake in Prime Medicine (NYSE:PRME) by 135.8% in Q3, acquiring an additional 3,155,182 shares to hold a total of 5,477,851 shares, valued at approximately $30.35 million. This boosted ARK's ownership to 4.07% of the company, which has a market cap of $743.7 million. Despite a recent 2.6% dip in share price to $4.12, institutional ownership of Prime Medicine remains high at 70.37%, and analysts currently maintain a "Moderate Buy" consensus with an average price target of $7.21.
LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases
LifeSci Capital has initiated coverage on Prime Medicine (PRME), emphasizing its potential for "one-and-done" curative treatments for liver and lung diseases using its prime editing technology. The firm highlights the broad applicability of prime editing, which enables precise gene modifications to address a wide range of genetic disorders. This initiation suggests a positive outlook on Prime Medicine's platform and its therapeutic prospects.
Prime Medicine CEO: FDA's new rare disease policies will lower costs
The CEO of Prime Medicine stated that the FDA's new policies regarding rare diseases are expected to lead to lower costs. This suggests a shift in regulatory approach aimed at making treatments for rare conditions more affordable, potentially benefiting both patients and the pharmaceutical industry.
Prime Medicine (NASDAQ:PRME) Upgraded by Lifesci Capital to "Strong-Buy" Rating
Lifesci Capital has upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating. This upgrade comes despite mixed analyst sentiment, with other firms issuing "sell" ratings, leading to a consensus of "Moderate Buy" for the early-stage biotech company. Prime Medicine reported an EPS of ($0.24) and revenue of $0.84 million for the quarter, with a market capitalization of approximately $763.6 million.
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives
Prime Medicine (PRME) reported a Q3 2025 net loss of US$50.6 million and trailing twelve-month losses of US$197 million, with revenue declining. This reinforces a bearish outlook, especially considering consistent quarterly losses despite fluctuating revenues and a high Price-to-Book ratio of 4.6x compared to industry averages. The company is in a heavy spend phase with no projected profit within the next three years, along with substantial shareholder dilution.
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Medicine (Nasdaq: PRME) has reported its full-year 2025 financial results, alongside significant business updates regarding its gene editing programs. The company plans to file IND/CTA for its Wilson Disease and Alpha-1 Antitrypsin Deficiency programs in the first half and mid-2026, respectively, with initial clinical data expected in 2027. Prime Medicine also reported a strong cash position of $191 million, which is expected to fund operations into 2027, and is in discussions with the FDA for accelerated approval of PM359 for Chronic Granulomatous Disease.
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Medicine, Inc. has reported its full-year 2025 financial results, showing a net loss of $201.1 million and cash reserves of $191.4 million, sufficient to fund operations into 2027. The company is advancing its gene editing pipeline, with plans to file IND/CTA for Wilson Disease and AATD programs in the first half and mid-2026, respectively, and expects initial clinical data for both in 2027. Prime Medicine is also engaging with the FDA regarding regulatory pathways for PM359 in CGD, anticipating accelerated approval based on breakthrough 2025 data.
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives
Prime Medicine (PRME) reported a Q3 2025 loss of US$50.6 million on US$1.2 million in revenue, with basic EPS loss of US$0.32. The company's trailing twelve-month losses are substantial at US$197.3 million, and quarterly losses consistently range from US$42 million to US$55 million despite modest revenue fluctuations. This financial performance, coupled with a P/B ratio of 4.6x and projected revenue declines, reinforces a cautious, bearish outlook among investors.
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives
Prime Medicine (PRME) recently reported FY 2025 Q3 results, revealing a total revenue of US$1.2 million and a basic EPS loss of US$0.32, with a net loss of US$50.6 million. Trailing twelve-month losses now total US$197 million, aligning with concerns about widening losses and the company remaining in a heavy spending phase. Bears also point to the company's 4.6x P/B ratio, significant shareholder dilution, and projected revenue declines as reasons for caution.
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) reported a Q4 loss of $0.22 per share, beating the Zacks Consensus Estimate of a $0.25 loss, but missed revenue estimates with $0.84 million against an expected $2.31 million. The company's shares have risen 34.3% year-to-date, outperforming the S&P 500's 0.5% gain, despite a mixed outlook with a Zacks Rank #3 (Hold). Investors are now looking to future earnings calls for management's commentary on the company's financial trajectory.
Prime Medicine (Nasdaq: PRME) details 2025 results, cash runway and gene-editing milestones
Prime Medicine reported its 2025 full-year financial results, showing an increased net loss of $201.1 million but improved collaboration revenue. The company detailed significant progress in its gene-editing pipeline, including breakthrough Phase 1/2 data for PM359 and plans for multiple IND/CTA filings in 2026 for Wilson Disease and Alpha-1 Antitrypsin Deficiency programs. With $191.4 million in cash, Prime Medicine expects to fund operations into 2027, emphasizing the advancement of its Prime Editing platform towards clinical validation and potential curative therapies.
Prime Medicine posts $201M loss advancing gene-editing therapies
Prime Medicine reported a net loss of $201.1 million for the full year 2025, with R&D expenses totaling $160.6 million. Despite the financial loss, the company affirmed a cash runway into 2027 with $191.4 million in cash and investments, and plans key regulatory filings for its Wilson Disease and AATD programs in 2026, with initial clinical data expected in 2027. Prime Medicine also continues engagement with the FDA for PM359 in CGD, anticipating an accelerated approval pathway.
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Medicine announced its full-year 2025 financial results, reporting a cash position of $191 million, which is expected to fund operations into 2027. The company is on track to file IND/CTA for its Wilson Disease and AATD programs in the first half and mid-2026 respectively, with initial clinical data anticipated in 2027. Prime Medicine is also engaging with the FDA for PM359 in CGD, with plans to submit a BLA following final alignment, supported by breakthrough data published in 2025.
Prime to test FDA flexibility with 2-patient gene editing submission
Prime Medicine aims to seek FDA approval for its gene-editing treatment, PM359, for chronic granulomatous disease (CGD) based on a two-patient study, despite previously deprioritizing the program due to economic reasons and the rarity of the condition. This bid will test the FDA's new initiatives to streamline innovative treatment approvals, including a "plausible mechanism" pathway that encouraged Prime to reconsider. If approved, it could provide a significant market opportunity and potentially yield a valuable priority review voucher for the company.
HighTower Advisors LLC Buys 312,401 Shares of Prime Medicine, Inc. $PRME
HighTower Advisors LLC significantly increased its stake in Prime Medicine, Inc. (NYSE:PRME) by 1,463% in Q3, purchasing 312,401 additional shares to own a total of 333,755 shares valued at $1.85 million. Other institutional investors like Alphabet Inc. and Sumitomo Mitsui Trust Group Inc. also increased their holdings. Prime Medicine, a clinical-stage genetic medicines company, currently has a "Moderate Buy" consensus rating from analysts with a target price of $7.21.
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc. announced its participation in three upcoming investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Jefferies Biotech on the Beach Summit, and The Citizens Life Sciences Conference. Management will participate in fireside chats and one-on-one meetings to discuss the company's proprietary Prime Editing platform and its diverse pipeline of genetic therapies. Live audio webcasts of the fireside chats will be available on the company's website.
Prime Medicine lines up three March investor talks in Boston and Miami Beach
Prime Medicine (Nasdaq: PRME) announced its management will participate in three investor conferences in early March 2026, including fireside chats at TD Cowen and Citizens Life Sciences, and one-on-one meetings at Jefferies Biotech on the Beach. Live audio webcasts of the fireside chats will be available on the company's website, with replays accessible for 90 days. Following this news, PRME's stock gained 7.83%, adding approximately $58 million to its valuation.
Stock Traders Buy Large Volume of Call Options on Prime Medicine (NYSE:PRME)
Prime Medicine (NYSE:PRME) experienced unusual options trading activity on Wednesday, with traders buying 3,638 call options, a 79% increase over typical daily volume, signaling bullish sentiment. Following this, PRME shares rose 4.8% to $4.02. Analysts maintain a "Moderate Buy" consensus with an average price target of $7.21, and institutional investors hold a significant 70.37% stake in the company.
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc. announced its participation in three upcoming investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference, the Jefferies Biotech on the Beach Summit, and The Citizens Life Sciences Conference. The company will host fireside chats and 1x1 meetings to discuss its proprietary Prime Editing platform and its diversified portfolio of investigational therapeutic programs. Live audio webcasts of the fireside chats will be available on the company's website.
Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company
Jacob Funds, in its Q4 2025 investor letter, highlighted Prime Medicine, Inc. (NASDAQ:PRME) as a new investment, expressing confidence in its next-generation gene therapy technology. The fund believes Prime Medicine's elegant and precise gene editing function could offer simpler and safer treatment options for various diseases. Despite the early stage of development, promising efficacy and safety signals from its first clinical trial fueled Jacob Funds' decision to invest.
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Brokerages
Seven brokerages have issued a "Moderate Buy" consensus rating for Prime Medicine, Inc. (NYSE:PRME), with an average 12-month price target of $7.21. The clinical-stage gene-editing company focuses on developing single-dose treatments for various diseases using its proprietary prime editing technology. Shares recently opened at $3.57 and saw a 10.2% increase, with institutional investors holding a significant portion of the stock.
Institutional Owners May Ignore Prime Medicine, Inc.'s (NASDAQ:PRME) Recent US$66m Market Cap Decline as Longer-term Profits Stay in the Green
Institutional investors, who hold 45% of Prime Medicine, Inc. (NASDAQ:PRME), may not be significantly concerned by the recent US$66m market cap decline due to strong longer-term returns. While they experienced an 8.9% drop last week, the company's one-year returns of 44% likely offset these losses. Key shareholders include institutions, private equity firms (20%), and insiders like David Liu, who holds 11% and is a top key executive, indicating alignment with shareholder interests.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) experienced a US$110 million decrease in market cap last week, but still benefited from 36% one-year gains. Institutions hold a significant 44% ownership in the company and are the largest group of shareholders. The top 8 shareholders collectively own more than half the company's shares, with insiders also holding a substantial stake.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) experienced a US$110m decrease in market cap last week, despite having benefited from 36% one-year gains. Institutions hold a significant 44% ownership in the company, making its stock price sensitive to their trading actions. The top 8 shareholders combined own 52% of the business, with insider ownership at 15%.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) experienced a US$110 million decrease in market cap last week, despite having benefited from 36% gains over the past year. Institutions hold 44% of the company, making its stock price sensitive to their trading actions, with the top 8 shareholders controlling 52% of the business. Insiders own 15%, while private equity firms hold 20% and the general public 15%.
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5
JonesTrading analyst Soumit Roy has reaffirmed a "buy" rating for Prime Medicine (PRME.US), maintaining a target price of $5. This analyst, according to TipRanks data, has a 27.5% success rate and an average return of -12.9% over the past year. The information is provided for informational purposes and does not constitute investment advice.
Prime Medicine (NASDAQ:PRME) Shares Up 10.5% - Here's Why
Prime Medicine (NASDAQ:PRME) saw its shares climb 10.5% during Thursday's trading session, reaching a high of $4.52 before settling at $4.43. This occurred despite the company reporting an earnings per share miss of ($0.32) against a consensus of ($0.28) and maintaining a negative net margin of -3,301.64%. Analyst sentiment is split, with one "Strong Buy" and one "Sell" rating, resulting in a "Moderate Buy" consensus for the biotechnology firm.
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Prime Medicine, Inc. $PRME
Sumitomo Mitsui Trust Group Inc. significantly increased its stake in Prime Medicine, Inc. (NYSE:PRME) by 127.7% in the third quarter, now owning 3,629,924 shares valued at approximately $20.11 million. Institutional investors collectively hold about 70.37% of the company's stock. Analysts currently rate Prime Medicine as a "Moderate Buy" with an average price target of $7.21, although individual targets show a wide range.
Prime Medicine (NASDAQ:PRME) Trading Down 7.9% - Should You Sell?
Prime Medicine (NASDAQ:PRME) saw its shares drop 7.9% to $3.97 on Thursday, with trading volume significantly below average. The company faces mixed analyst ratings, ranging from "strong-buy" to "sell," resulting in a "Moderate Buy" consensus from MarketBeat. Financially, Prime Medicine reported weak fundamentals in its latest quarter, including missed EPS estimates, low revenue, and a very negative net margin.
Prime Medicine (NASDAQ:PRME) Shares Up 8.4% - Should You Buy?
Prime Medicine (NASDAQ:PRME) saw its shares jump 8.4% to $4.51 during mid-day trading on Wednesday, though with lower-than-average volume. Analyst opinions are divided, with Lifesci Capital upgrading it to a "strong-buy" while Weiss Ratings and Wall Street Zen downgraded it to "sell," leading to a "Moderate Buy" consensus on MarketBeat. The company reported a wider-than-expected quarterly EPS loss and low revenue, reflecting negative margins as it continues to develop its Prime Editing gene-therapy platform.
Prime Medicine updates corporate strategy for Prime Editing platform
Prime Medicine (PRME) has announced an updated corporate strategy for its Prime Editing platform, detailing clinical and regulatory timelines for its programs in liver, lung, and oncology indications. The company plans to file regulatory applications and initiate Phase 1 trials for liver-focused candidates PM577 and PM647 in 2026, with initial clinical data expected in 2027. Prime Medicine aims to expand its pipeline organically and through partnerships, leveraging its gene-editing technology for broad therapeutic potential.
Prime Medicine, Inc. Updates on Prime Editing Developments
Prime Medicine, Inc. has provided updates on its Prime Editing technology, detailing advancements and anticipated milestones for 2026. The company expects to file IND/CTA applications for Wilson Disease and AATD in the first half and mid-2026, respectively, and shared positive early Phase 1/2 data for its CGD treatment. Prime Medicine's platform is projected to address over 90% of genetic diseases, with potential for significant milestones from a partnership with Bristol Myers Squibb.
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
Prime Medicine, Inc. announced that CEO Allan Reine, M.D., will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will cover the company's proprietary Prime Editing platform, a versatile gene editing technology focused on developing one-time curative genetic therapies. A live audio webcast will be available on the company’s website, with a replay accessible for 90 days.
Prime Medicine (NYSE:PRME) Trading Down 3.3% - Here's What Happened
Prime Medicine (NYSE:PRME) experienced a 3.3% drop in its stock price during mid-day trading, with a significant decline in trading volume. This comes amidst mixed analyst ratings, with some firms maintaining bullish price targets while Citigroup cut its target to $4.25, leading to a consensus "Moderate Buy" rating. The company, a clinical-stage genetic medicines firm, has a market capitalization of $610.49 million, and institutional investors collectively own 70.37% of the stock.
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases
LifeSci Capital initiated coverage on Prime Medicine (PRME) with an Outperform rating and a $6 price target, citing the company's "one-and-done" gene editing treatments for conditions like Wilson’s disease, alpha-1 antitrypsin deficiency, and cystic fibrosis. Separately, Prime Medicine announced the publication of successful Phase 1/2 clinical data for its investigational therapy, PM359, used to treat p47phox chronic granulomatous disease, demonstrating the safety and efficacy of Prime Editing. The trial results showed rapid neutrophil and platelet engraftment and sustained clinical improvement in two patients.
